Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Madeleine Johnson headshot

Here's Why Arena Pharmaceuticals (ARNA) Stock is Skyrocketing Today

On Tuesday, shares of biopharmaceutical company Arena Pharmaceuticals (ARNA) are skyrocketing, up about 41% to $26.10 per share in afternoon trading after it reported positive mid-stage trial results for one of its drugs.

    Arena's Ralinepag Positive in Phase II PAH Study, Shares Up

    Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.

      Novartis' Cosentyx Superior to Stelara in Psoriasis Study

      Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,

        Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical

        Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical

          Microsoft Unveils Software to Enhance Employee Productivity

          Microsoft Corp. (MSFT) recently launched its long awaited employee performance analysis software called Workplace Analytics.

            Geron Stock Up Almost 40% So Far This Year After '16 Decline

            Geron Corporation's (GERN) shares have risen 38.7% this year so far, outperforming the Zacks classified Medical - Biomedical and Genetics industry, which rose 5.6%. This comes after a decline of more than 57% in 2016.

              Cardiome's Partner SteadyMed Submits NDA for PAH Injection

              Cardiome Pharma Corp. (CRME) announced that its partner SteadyMed Ltd. (STDY) has submitted a new drug application (NDA) to the FDA for its lead candidate, Trevyent (treprostinil injection), for treatment of pulmonary arterial hypertension (PAH).

                Alkermes Presents Phase III Data on Schizophrenia Candidate

                Alkermes plc (ALKS) announced positive preliminary top-line results from a phase III study, ENLIGHTEN-1, evaluating its schizophrenia candidate, ALKS 3831.

                  Arena Ends Study on Extended Release Formulation of PAH Drug

                  Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.

                    Sheraz Mian headshot

                    Top Research Reports for JNJ, AT&T & Lockheed Martin

                    Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), AT&T (T), and Lockheed Martin (LMT).

                      Aduro Starts Phase II Combo Study with CRS-207 & Keytruda

                      Aduro Biotech, Inc. (ADRO) has announced initiation of a phase II study to evaluate a combination therapy of its lead candidate, CRS-207, in combination with Keytruda, for treatment of patients with pleural mesothelioma (MPM).

                        Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                        Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca

                          Nilanjan Choudhury headshot

                          How to Interpret Big Oil's Support for a Carbon Tax

                          Surprisingly, some of the biggest energy companies have joined the call advocating for a progressively rising carbon tax.

                            Arpita Dutt headshot

                            Better Days Ahead for the Pharma Sector?

                            Sales, R&D, strong results, and a higher number of FDA approvals.

                              Gilead's (GILD) HCV Drug Application Accepted in the EU

                              Gilead Sciences, Inc. (GILD) announced that the CHMP has adopted a positive opinion on the company's application for HCV drug Vosevi.

                                Sweta Killa headshot

                                Healthcare ETF (IYH) Hits New 52-Week High

                                This healthcare ETF hit a new 52-week high. Are more gains in store for this ETF?

                                  Here's Why Geron (GERN) is a Good Stock to Invest in Now

                                  Geron Corporation (GERN) is developing anti-cancer therapies based on telomerase inhibitors.

                                    Fitch Sees Fastest Global Growth in 10 Years: ETFs To Buy

                                    Credit rating agency Fitch expects the global growth to reach 2.9% in 2017 and 3.1% in 2018.

                                      Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US

                                      Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older

                                        Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago

                                        Zacks.com featured highlights: Johnson & Johnson, NantKwest, Delek US Holdings, Abbot Labs and Winnebago

                                          J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study

                                          Johnson & Johnson (JNJ) announced a three-year follow-up data from a late stage study, evaluating its cancer drug Imbruvica against Pfizer's Torisel for treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

                                            AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?

                                            AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.

                                              Company News for June 19, 2017

                                              Companies in the News are: FNSR,JNJ,BHP,DOW,DD

                                                J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

                                                Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

                                                  J&J's Invokana Lowers Heart Issues, Raises Amputation Risk

                                                  Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.